Clinical trials: Adenocarcinoma of the Prostate
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00039104
- Testing
- rebimastat, zoledronic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003633
- Testing
- docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Prostate Cancer
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
- Trial name
- NCT00005028
- Testing
- bryostatin 1, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Maryland, Baltimore
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00087139
- Testing
- ixabepilone
- Where
- 162 sites in United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
This phase I trial studies the side effects and the best dose of Akt inhibitor MK2206 together with hydroxychloroquine in treating patients with advanced solid tumors, melanoma, prostate or kidney cancer.
- Conditions
- Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- NCT01480154
- Testing
- Akt Inhibitor MK2206, Hydroxychloroquine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Prostate Adenocarcinoma
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Patients will receive a single dose of 68Ga-PSMA-11 and undergo a PET/CT or PET/MRI imaging study.
- Trial name
- NCT05197257
- Testing
- Ga-PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer, Prostate Adenocarcinoma
Trial of NanoPac Focal Therapy for Prostate Cancer
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm
- Trial name
- NCT04221828
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- NanOlogy, LLC
Prostate Cancer
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy may be an effective treatment for prostate cancer.
- Trial name
- NCT00002480
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Adenocarcinoma
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
- Trial name
- RAD 2003 (NCT04743934)
- Testing
- Flibanserin 100 MG, Androgen deprivation therapy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrew McDonald
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer.
- Trial name
- NCT04384770
- Testing
- CT-guided Stereotactic Body Radiation Therapy, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
This research trial studies cell-free deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in blood from patients with prostate cancer that does not respond to hormone therapy and has spread to other places in the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT02853097
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Southern California
Prostate Cancer
Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
The purpose of this study is to observe PSA response and incidence of side effects in patients diagnosed with intermediate to high risk prostate cancer and treated with Cesium-131 in combination of external beam therapy.
- Trial name
- NCT00621413
- Where
- 9 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- IsoRay Medical, Inc.
Prostate Cancer
Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance
This phase 2 waitlist-controlled, randomized trial is designed to compare the difference in proliferative index (Ki67) between carbohydrate restricted diet and usual care over a 6 month period in men with prostate cancer who have…
- Trial name
- NCT03679260
- Testing
- Carbohydrate restricted diet, Non-restricted diet, Phone counseling with dietitian
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer, Prostate Adenocarcinoma
Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT)
Radiotherapy (RT) of the abdomen and/or pelvis is known to cause acute and late gastrointestinal (GI) toxicities. While radiation dose and volume are known risk factors for developing such side effects, recent evidence suggests…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostatic Neoplasms
- Trial name
- IMPRINT (NCT04638049)
- Testing
- Collection of human biofluids, Patient reported outcome measures
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University Hospital, Ghent
Prostate Adenocarcinoma
Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma
Patients with locally confined prostate adenocarcinoma (clinical stage T1c - T2bN0M0, Gleason score 7, PSA 20 ng/ml) are assigned to one of two treatment arms.
- Trial name
- NCT02339948
- Testing
- SBRT
- Where
- 4 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- GenesisCare USA